Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica [Internet]. 2009Sep.30 [cited 2026Nov.5];94(10):1362-7. Available from: https://haematologica.org/article/view/5371